HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

First quarter razors and blades division profit jumped $7.6 mil. to $46.6 mil. on "lower advertising and promotional spending compared to last year's higher spending related to the launch of Quattro in several European markets, as well as lower selling and administrative expenses," firm reports Jan. 23. However, razor and blade sales dropped 5% to $216.1 mil. including impact from currency. Excluding currency, Quattro sales were up 30% over the same quarter last year "on incremental sales from Quattro for Women and Quattro Power," Energizer notes, adding older products offset Quattro gains. Company held a 20.7% overall share in the wet shave category in primary markets for the year ending November 2005, versus 21.5% in the prior year. Net earnings in Q1 were flat at $120.5 mil. and net sales were up $6.5 mil. to $882.4 mil...

You may also be interested in...

GermBloc Hand-Sanitizer Class Action Takes Aim At 99.99% Germ-Killing Claim

Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.

Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC

The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.

Virtual Adcom Vet Says In-Person Events May Be Better For Product Approval Recommendations

Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts